Amarin Corp Plcuk (AMRN)
AI stock analysis · as of Jun 5, 2026
Loading microstructure…
Amarin is a single-product cardiovascular pharma company built around VASCEPA/VAZKEPA (icosapent ethyl), now in transition from a U.S. branded sales model—being eroded by 11+ approved generics—to a global royalty-and-supply model anchored by a 2025 Recordati deal covering 59 European countries and a $70M annual cost-cut restructuring. The core investment question is whether the European royalty stream, ex-U.S. partner launches, and a leaner cost base can stabilize cash flow and create real equity value before the U.S. business continues to decline and litigation/generic risk further compresses the franchise.
valuationOptically cheap on P/B (0.66x) and P/S (1.36x) with net cash ~45% of market cap, but expensive on forward P/E of 14.3x and negative EV/EBITDA—fairly priced as an option on the Recordati royalty story rather than a clear bargain.
This analysis is from Jun 5, 2026. Want the latest on AMRN, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Trades at 0.66x price/book and 1.36x sales with $134.7M cash vs only $6.1M debt and ~$295M market cap—roughly half the enterprise value is net cash, providing meaningful downside cushion
- · FCF turned positive ($6.7M latest) and 2025 net loss narrowed sharply to -$38.8M from -$82.2M in 2024, with the $70M annual cost-out from the June 2025 Global Restructuring Plan still to flow through fully
- · Recordati partnership shifts European economics to a high-margin royalty model across 59 countries, with European exclusivity protected through 2039 via the April 2024 patent grant—insulating the ex-U.S. franchise from the generic dynamics plaguing the U.S.
- · Expanding reimbursement wins (Italy, Austria, Slovenia in 2025) and partner launches (Australia/CSL, Israel/Neopharm, South Korea/Singapore via Lotus) provide a multi-year royalty ramp
- · Over 70 medical societies endorse IPE use with fresh 2025 AHA/ESC statements, supporting durable physician adoption regardless of branded vs. generic supply
- · Gross margin rebounded to 56.6% in 2025 from 35.6% in 2024 as mix shifts toward higher-margin licensing/royalty revenue
Bear case
- · U.S. franchise is structurally impaired: 11+ ANDA holders approved and June 2025 Supreme Court skinny-label ruling removes a key defensive tool, making U.S. revenue recovery essentially impossible
- · Revenue declined -6.5% YoY in 2025 and dropped from $307M (2023) to $214M (2025)—a 30% top-line erosion in two years with no clear inflection visible
- · Single-product, single-partner concentration: European success now depends almost entirely on Recordati's execution and country-by-country reimbursement, which is unpredictable and can compress royalty economics
- · Three U.S. wholesalers dominate receivables/revenue, layering counterparty concentration on top of generic-driven volume decline
- · Negative EV/EBITDA (-2,427x) and -17.8% operating margin show the business is still structurally unprofitable; the $70M cost-cut is necessary but not sufficient if revenue continues to decline
- · Debt/equity of 1.71 despite minimal debt implies a thin/eroding equity base from accumulated deficits, and large NOLs carry full valuation allowances signaling management itself doesn't underwrite near-term profitability
Catalysts
- · July 29, 2026 earnings: first clean look at full cost-savings run-rate and Recordati royalty contribution
- · Sequential European national reimbursement decisions across remaining Recordati territories—each adds incremental royalty base
- · Evidence of sustained positive FCF for multiple consecutive quarters, which could trigger re-rating from a 'melting ice cube' multiple
- · Potential strategic alternatives/M&A: with $135M cash, sub-$300M market cap, European exclusivity to 2039, and a simplified royalty model, Amarin is increasingly buyout-shaped
- · Short interest at 3.0% of float and 7.5 days-to-cover is modest but elevated enough that a positive earnings surprise could squeeze
- · EPA + GLP-1 combination research and new clinical publications (45 in 2025) could expand the addressable narrative if data is supportive
Key risks
- · Continued U.S. revenue decline outpacing European royalty ramp, leaving consolidated revenue and cash flow falling
- · Recordati execution shortfall or unfavorable reimbursement pricing in major European markets materially impairs the royalty thesis
- · Restructuring disruption: cutting most European commercial headcount could backfire if Recordati handoff is rocky
- · Further adverse legal outcomes—six identified litigation matters plus international patent challenges—could narrow exclusivity
- · Going-concern dynamics if cash burn re-accelerates: current cash buffer is ~4 years at current burn but only ~1 year if losses widen back to 2024 levels
What to watch
- · July 29, 2026 earnings—watch for Recordati royalty disclosure and updated cash burn trajectory
- · European reimbursement announcements in remaining Recordati countries through 2026
- · U.S. branded revenue erosion rate quarter-over-quarter post-skinny-label ruling
- · Cash balance trend—staying above ~$120M signals the model is self-sustaining
- · 52-week support at $11.65 and resistance at $20.90; any breach of $11.65 would signal fundamental deterioration
- · Short interest changes ahead of earnings given 7.5-day cover ratio
Key metrics
Price target rationale
Base case ~$14 reflects ~1.3x P/S on stabilizing ~$215M revenue plus net cash, in line with current trading. Bull case ~$19 assumes Recordati royalties ramp visibly, full $70M cost-out flows through to sustained positive FCF, and the market re-rates toward 1.8x sales or a takeout multiple. Bear case ~$9 assumes continued mid-single-digit revenue decline, Recordati ramp disappoints, and shares converge to ~tangible book/net cash floor near $5-6 plus modest going-concern discount on the operating business.
On Wall Street's view (mixed): The $12.50 consensus mean (only 2 analysts) sits ~11% below the current $14.06 price and reflects justified caution given the Supreme Court skinny-label ruling and continued top-line decline. I agree directionally that upside is capped near-term, but the consensus may under-weight the net cash cushion and the cost-out impact on 2026 cash flow.
Latest filing (10-K)
Amarin is a one-product cardiovascular company whose U.S. branded VASCEPA business is being hollowed out by generics while it pivots to a royalty-and-supply model globally, anchored by a transformative 2025 Recordati deal covering 59 European countries and a $70 million cost-cut that will determine whether the company can generate sustainable cash flow.
Amarin Corporation plc is a pharmaceutical company focused on cardiovascular health, commercializing VASCEPA (icosapent ethyl, branded VAZKEPA in Europe), an omega-3 fatty acid approved by the FDA in 2012 for severe hypertriglyceridemia and in 2019 for reducing cardiovascular events in high-risk statin-treated patients. The company earns revenue through direct U.S. product sales, product supply to international partners, and licensing/royalty fees from seven commercial partners across Europe, Canada, Australia, China, the Middle East, Southeast Asia, and Israel. In June 2025, Amarin signed an exclusive long-term license and supply agreement with Recordati covering 59 countries in Europe, shifting European commercialization responsibility to Recordati while Amarin retains supply and royalty economics.
What the news says · neutral
The dominant near-term storyline is the Supreme Court's June 4 ruling upholding 'skinny labels' for generics, a direct blow to Amarin's ability to protect Vascepa from generic competition and a meaningful negative catalyst. Offsetting this somewhat is a longer-term narrative of operational resilience: overseas sales and cost discipline kept cash flow positive in Q1 2026, a Strong Buy upgrade appeared in May, and analyst fair-value targets have clustered around $12 across multiple reports. However, Q4 2025 showed topline contraction, and the generic competition threat now appears structurally harder to fight, which clouds the revenue recovery story. Overall, the stock faces a significant legal headwind that likely caps near-term upside despite some positive operational signals.
This analysis is from Jun 5, 2026. Markets move. Get the current read on AMRN and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.